Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-90002 · 1 trial · 1 indication
Number of participants with a DLT
Dose at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1.
Dose that is the last dose level below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during Cycle 1.
Dose at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1.
Dose that is the last dose level below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during Cycle 1.
| Arm | Type | Description |
|---|---|---|
| Part A: CC-90002 | EXPERIMENTAL | CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle |
| Part B: CC-90002 with Rituximab | EXPERIMENTAL | CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL |
| Name | Type | Description |
|---|---|---|
| CC-90002 | DRUG | - |
| Rituximab | DRUG | - |
Inclusion Criteria: 1. Men and women, 18 years or older, with advanced, relapsed or refractory solid tumors, Multiple Myeloma (MM) or non-Hodgkin's lymphoma (NHL) in Part A. In Part B, relapsed and/or refractory CD20-positive NHL subjects only. 2. At least one site of measurable disease in subjects...
CC-90002 is an investigational small molecule developed by Bristol-Myers Squibb for hematologic neoplasms, a group of blood cancers. It was studied in a Phase 1 dose-finding trial in patients with advanced solid and hematologic cancers. CC-90002 is not approved and remains in clinical development.
CC-90002 was evaluated for the treatment of hematologic neoplasms, which include blood cancers. It was tested in a Phase 1 trial that enrolled 60 patients with advanced solid and hematologic cancers. The study is completed, and CC-90002 has not been approved for any indication.
CC-90002 is made by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. Bristol-Myers Squibb developed and sponsored the clinical program for CC-90002 in hematologic neoplasms.
CC-90002 is in Phase 1 development. It was studied in a single Phase 1 dose-finding trial in patients with advanced solid and hematologic cancers. That trial is completed, and CC-90002 is investigational and not approved for any use.
CC-90002 was studied in one clinical trial, NCT02367196, titled A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers. The trial enrolled 60 patients across the United States and Spain and is completed.
CC-90002 is not FDA approved. It is an investigational small molecule that completed a Phase 1 dose-finding trial in patients with advanced solid and hematologic cancers. Bristol-Myers Squibb has not announced approval for CC-90002 in hematologic neoplasms or any other indication.